FGF2 has been reported to be involved in the resistance to anticancer agents, both cytotoxic chemotherapeutic and molecular-targeted, in various malignant tumors including lung cancer [14, 18, 19, 20, 21, 22, 23]. Here, FGF2 is linked to lung cancer.